Steward Partners Investment Advisory LLC Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Steward Partners Investment Advisory LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 16.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 260,293 shares of the company’s stock after selling 51,360 shares during the period. Johnson & Johnson accounts for 0.6% of Steward Partners Investment Advisory LLC’s portfolio, making the stock its 28th largest holding. Steward Partners Investment Advisory LLC’s holdings in Johnson & Johnson were worth $40,798,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Genus Capital Management Inc. increased its stake in Johnson & Johnson by 247.0% in the third quarter. Genus Capital Management Inc. now owns 7,780 shares of the company’s stock worth $1,212,000 after purchasing an additional 5,538 shares during the period. Trifecta Capital Advisors LLC increased its position in shares of Johnson & Johnson by 0.8% during the third quarter. Trifecta Capital Advisors LLC now owns 20,015 shares of the company’s stock worth $3,117,000 after acquiring an additional 167 shares during the period. Wakefield Asset Management LLLP raised its stake in shares of Johnson & Johnson by 498.8% during the third quarter. Wakefield Asset Management LLLP now owns 16,341 shares of the company’s stock valued at $2,545,000 after acquiring an additional 13,612 shares in the last quarter. Centerpoint Advisors LLC grew its stake in Johnson & Johnson by 2.2% in the third quarter. Centerpoint Advisors LLC now owns 12,388 shares of the company’s stock worth $1,929,000 after purchasing an additional 272 shares in the last quarter. Finally, Berkshire Bank increased its stake in shares of Johnson & Johnson by 1.4% during the third quarter. Berkshire Bank now owns 21,857 shares of the company’s stock valued at $3,404,000 after buying an additional 311 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Bank of America decreased their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, May 6th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.86.

Check Out Our Latest Stock Analysis on JNJ

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $0.19 during mid-day trading on Wednesday, reaching $144.57. 1,663,540 shares of the stock traded hands, compared to its average volume of 7,356,035. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The business has a 50-day moving average of $150.88 and a 200 day moving average of $155.08. The stock has a market capitalization of $347.93 billion, a PE ratio of 9.00, a PEG ratio of 2.44 and a beta of 0.55. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same period in the previous year, the firm earned $2.68 EPS. Johnson & Johnson’s revenue was up 2.3% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.64 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be given a $1.24 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.43%. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.